The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium.

Ilipilla, Geeta; Arnold, L Eugene

Ilipilla, Geeta; Arnold, L Eugene.

Afiliación

Ilipilla G; Department of Psychiatry and Behavioral Health, Nationwide Childrens Hospital, Columbus, OH, USA.
Arnold LE; Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Health, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Expert Opin Pharmacother ; 25(8): 945-956, 2024 Jun.

Article en En | MEDLINE | ID: mdl-38900676

ABSTRACT

ABSTRACT

INTRODUCTION:

Adrenergic neurotransmitter reuptake inhibitors are gaining attention in treatment for attention-deficit hyperactivity disorder (ADHD). Due to their effects on norepinephrine, dopamine, and serotonin neurotransmission, they benefit both ADHD and comorbid disorders and have some other advantages including longer duration of action and fewer adverse effects compared to stimulants. There is continued interest in these agents with novel mechanisms of action in treatment of ADHD. AREAS COVERED The authors conducted a PubMed literature search using the following key words 'ADHD' AND 'adrenergic reuptake inhibitors' OR 'nonstimulants' OR 'atomoxetine' OR 'Viloxazine' OR 'Dasotraline' OR 'Centanafadine' OR 'PDC-1421' OR 'Reboxetine' OR 'Edivoxetine' OR 'Bupropion' OR 'Venlafaxine' OR 'Duloxetine.' They reviewed FDA fact sheets of available medications for safety/tolerability studies and reviewed published clinical studies of these medications for treatment of ADHD. EXPERT OPINION Adrenergic neurotransmitter reuptake inhibitors fit the diverse needs of children and adolescents with ADHD with 1) poor tolerability to stimulants (e.g. due to growth suppression, insomnia, rebound irritability, co-morbid depression, anxiety and tic disorders, substance abuse or diversion concerns), 2) cardiac risks, and/or 3) need for extended duration of action. Their differences in receptor affinities and modulating effects support the unique benefits of individual agents.

Asunto(s)

Trastorno por Déficit de Atención con Hiperactividad; Humanos; Trastorno por Déficit de Atención con Hiperactividad/tratamiento farmacológico; Niño; Adolescente; Inhibidores de Captación Adrenérgica/uso terapéutico; Inhibidores de Captación Adrenérgica/farmacología; Inhibidores de Captación Adrenérgica/efectos adversos; Estimulantes del Sistema Nervioso Central/uso terapéutico; Estimulantes del Sistema Nervioso Central/efectos adversos; Estimulantes del Sistema Nervioso Central/farmacología; Animales; Inhibidores de la Captación de Neurotransmisores/uso terapéutico; Inhibidores de la Captación de Neurotransmisores/farmacología; Inhibidores de la Captación de Neurotransmisores/efectos adversos

Palabras clave

ADHD; Adrenergic agents; adrenergic neurotransmitter reuptake inhibitors; medication; non-stimulants

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastorno por Déficit de Atención con Hiperactividad Límite: Adolescent / Animals / Child / Humans Idioma: En Revista: Expert Opin Pharmacother Asunto de la revista: FARMACOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google